Nosocomial Pneumonia. Lessons Learned.

Critical Care Clinics

Volumn 29, Issue 3, 2013, Pages 521-546

  Nair, Girish B ^a   Niederman, Michael S ^a,b  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

Antimicrobial treatment; Health care associated pneumonia; Hospital acquired pneumonia; Nosocomial pneumonia; Prevention; Ventilator associated complications; Ventilator associated pneumonia

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AZTREONAM; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN; CIPROFLOXACIN; CLINDAMYCIN; COLISTIN; ERTAPENEM; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; PENICILLINASE; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; QUINOLONE; TELAVANCIN; TIGECYCLINE; TOBRAMYCIN; VANCOMYCIN;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTIFICIAL VENTILATION; DRUG EFFICACY; ENDOTRACHEAL INTUBATION; ENDOTRACHEAL TUBE CUFF; ENTEROBACTER; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; HOSPITAL ACQUIRED PNEUMONIA; INFECTION RISK; KLEBSIELLA; LEGIONELLA; MALNUTRITION; MORTALITY; NOCARDIA; PATHOGENESIS; PNEUMOCYSTIS JIROVECI; PRIORITY JOURNAL; PROTEUS; PSEUDOMONAS AERUGINOSA; REVIEW; SERRATIA MARCESCENS; SMOKING; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TOTAL PARENTERAL NUTRITION; TREATMENT DURATION; TREATMENT FAILURE; VENTILATOR ASSOCIATED PNEUMONIA;

ANTIMICROBIAL TREATMENT; HEALTH CARE-ASSOCIATED PNEUMONIA; HOSPITAL-ACQUIRED PNEUMONIA; NOSOCOMIAL PNEUMONIA; PREVENTION; VENTILATOR-ASSOCIATED COMPLICATIONS; VENTILATOR-ASSOCIATED PNEUMONIA;

AGE DISTRIBUTION; ANTI-INFECTIVE AGENTS; COMORBIDITY; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE; HUMANS; IMMUNOCOMPROMISED HOST; PNEUMONIA; PNEUMONIA, VENTILATOR-ASSOCIATED; RISK FACTORS; VENTILATORS, MECHANICAL;

EID: 84880043968     PISSN: 07490704     EISSN: 15578232     Source Type: Journal    
DOI: 10.1016/j.ccc.2013.03.007     Document Type: Review

References (87)

1. Vincent J.L., Rello J., Marshall J., et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009, 302(21):2323-2329.
2. Niederman M.S., Craven D., Bonten M.J., et al. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171(4):388-416.
3. Brito V., Niederman M.S. Healthcare-associated pneumonia is a heterogeneous disease, and all patients do not need the same broad-spectrum antibiotic therapy as complex nosocomial pneumonia. Curr Opin Infect Dis 2009, 22(3):316-325.
4. Safdar N., Dezfulian C., Collard H.R., et al. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med 2005, 33(10):2184-2193.
5. Rello J., Ollendorf D.A., Oster G., et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002, 122(6):2115-2121.
6. Dudeck M.A., HT National Healthcare Safety Network (NHSN) report, data summary for 2010, device-associated module 2010, CDC, Available at:. http://www.cdc.gov/nhsn/PDFs/dataStat/NHSN-Report_2010-Data-Summary.pdf.
7. Niederman M.S. Hospital-acquired pneumonia, health care-associated pneumonia, ventilator-associated pneumonia, and ventilator-associated tracheobronchitis: definitions and challenges in trial design. Clin Infect Dis 2010, 51(Suppl 1):S12-S17.
8. Klompas M. Is a ventilator-associated pneumonia rate of zero really possible?. Curr Opin Infect Dis 2012, 25(2):176-182.
9. Bonten M.J., Bergmans D.C., Ambergen A.W., et al. Risk factors for pneumonia, and colonization of respiratory tract and stomach in mechanically ventilated ICU patients. Am J Respir Crit Care Med 1996, 154(5):1339-1346.
10. Rotstein C., Evans G., Born A., et al. Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults. Can J Infect Dis Med Microbiol 2008, 19(1):19-53.
11. Craven D.E., Chroneou A., Zias N., et al. Ventilator-associated tracheobronchitis: the impact of targeted antibiotic therapy on patient outcomes. Chest 2009, 135(2):521-528.
12. Dallas J., Skrupky L., Abebe N., et al. Ventilator-associated tracheobronchitis in a mixed surgical and medical ICU population. Chest 2011, 139(3):513-518.
13. Craven D.E., Hjalmarson K. Prophylaxis of ventilator-associated pneumonia: changing culture and strategies to trump disease. Chest 2008, 134(5):898-900.
14. Nseir S., Favory R., Jozefowicz E., et al. Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study. Crit Care 2008, 12(3):R62.
15. Skerrett S.J., Niederman M.S., Fein A.M. Respiratory infections and acute lung injury in systemic illness. Clin Chest Med 1989, 10(4):469-502.
16. Campbell D.G., Niederman M.S., Broughton W.A., et al. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement, American Thoracic Society, November 1995. Am J Respir Crit Care Med 1996, 153(5):1711-1725.
17. Waterer G.W., Quasney M.W., Cantor R.M., et al. Septic shock and respiratory failure in community-acquired pneumonia have different TNF polymorphism associations. Am J Respir Crit Care Med 2001, 163(7):1599-1604.
18. Jones R.N. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 2010, 51(Suppl 1):S81-S87.
19. Trouillet J.L., Chastre J., Vuagnat A., et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998, 157(2):531-539.
20. Fagon J.Y., Chastre J., Domart Y., et al. Nosocomial pneumonia in patients receiving continuous mechanical ventilation. Prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques. Am Rev Respir Dis 1989, 139(4):877-884.
21. Kollef M.H. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000, 31(Suppl 4):S131-S138.
22. El Solh A.A., Pietrantoni C., Bhat A., et al. Indicators of potentially drug-resistant bacteria in severe nursing home-acquired pneumonia. Clin Infect Dis 2004, 39(4):474-480.
23. Ewig S., Klapdor B., Pletz M.W., et al. Nursing-home-acquired pneumonia in Germany: an 8-year prospective multicentre study. Thorax 2012, 67(2):132-138.
24. Cook D.J., Walter S.D., Cook R.J., et al. Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients. Ann Intern Med 1998, 129(6):433-440.
25. Perbet S., Mongardon N., Dumas F., et al. Early-onset pneumonia after cardiac arrest: characteristics, risk factors and influence on prognosis. Am J Respir Crit Care Med 2011, 184(9):1048-1054.
26. Nseir S., Zerimech F., Fournier C., et al. Continuous control of tracheal cuff pressure and microaspiration of gastric contents in critically ill patients. Am J Respir Crit Care Med 2011, 184(9):1041-1047.
27. Bekaert M., Timsit J.F., Vansteelandt S., et al. Attributable mortality of ventilator-associated pneumonia: a reappraisal using causal analysis. Am J Respir Crit Care Med 2011, 184(10):1133-1139.
28. Heyland D.K., Cook D.J., Griffith L., et al. The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group. Am J Respir Crit Care Med 1999, 159(4 Pt 1):1249-1256.
29. Tejerina E., Frutos-Vivar F., Restrepo M.I., et al. Incidence, risk factors, and outcome of ventilator-associated pneumonia. JCrit Care 2006, 21(1):56-65.
30. Craven D.E., Hjalmarson K.I. Ventilator-associated tracheobronchitis and pneumonia: thinking outside the box. Clin Infect Dis 2010, 51(Suppl 1):S59-S66.
31. Niederman M.S. The argument against using quantitative cultures in clinical trials and for the management of ventilator-associated pneumonia. Clin Infect Dis 2010, 51(Suppl 1):S93-S99.
32. Heyland D., Cook D., Dodek P., et al. Arandomized trial of diagnostic techniques for ventilator-associated pneumonia. NEngl J Med 2006, 355(25):2619-2630.
33. Pugin J., Auckenthaler R., Mili N., et al. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid. Am Rev Respir Dis 1991, 143(5 Pt 1):1121-1129.
34. Singh N., Rogers P., Atwood C.W., et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000, 162(2 Pt 1):505-511.
35. Luna C.M., Blanzaco D., Niederman M.S., et al. Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med 2003, 31(3):676-682.
36. Zilberberg M.D., Shorr A.F. Ventilator-associated pneumonia: the clinical pulmonary infection score as a surrogate for diagnostics and outcome. Clin Infect Dis 2010, 51(Suppl 1):S131-S135.
37. Shorr A.F., Cook D., Jiang X., et al. Correlates of clinical failure in ventilator-associated pneumonia: insights from a large, randomized trial. JCrit Care 2008, 23(1):64-73.
38. Klompas M., Khan Y., Kleinman K., et al. Multicenter evaluation of a novel surveillance paradigm for complications of mechanical ventilation. PLoS One 2011, 6(3):e18062.
39. Hayashi Y., Morisawa K., Klompas M., et al. Toward improved surveillance: the impact of ventilator-associated complications on length of stay and antibiotic use in patients in intensive care units. Clin Infect Dis 2013, 56(4):471-477.
40. Klompas M., Kleinman K., Khan Y., et al. Rapid and reproducible surveillance for ventilator-associated pneumonia. Clin Infect Dis 2012, 54(3):370-377.
41. Klompas M., Magill S., Robicsek A., et al. Objective surveillance definitions for ventilator-associated pneumonia. Crit Care Med 2012, 40(12):3154-3161.
42. Fagon J.Y. Biological markers and diagnosis of ventilator-associated pneumonia. Crit Care 2011, 15(2):130.
43. Gibot S., Cravoisy A., Levy B., et al. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. NEngl J Med 2004, 350(5):451-458.
44. Anand N.J., Zuick S., Klesney-Tait J., et al. Diagnostic implications of soluble triggering receptor expressed on myeloid cells-1 in BAL fluid of patients with pulmonary infiltrates in the ICU. Chest 2009, 135(3):641-647.
45. Luyt C.E., Guerin V., Combes A., et al. Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. Am J Respir Crit Care Med 2005, 171(1):48-53.
46. Bouadma L., Luyt C.E., Tubach F., et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010, 375(9713):463-474.
47. Tang H., Huang T., Jing J., et al. Effect of procalcitonin-guided treatment in patients with infections: a systematic review and meta-analysis. Infection 2009, 37(6):497-507.
48. Iregui M., Ward S., Sherman G., et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002, 122(1):262-268.
49. Wunderink R.G., Niederman M.S., Kollef M.H., et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012, 54(5):621-629.
50. Freire A.T., Melnyk V., Kim M.J., et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010, 68(2):140-151.
51. Heyland D.K., Dodek P., Muscedere J., et al. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med 2008, 36(3):737-744.
52. Trouillet J.L., Vuagnat A., Combes A., et al. Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms. Clin Infect Dis 2002, 34(8):1047-1054.
53. Niederman M.S. Reexamining quinolone use in the intensive care unit: use them right or lose the fight against resistant bacteria. Crit Care Med 2005, 33(2):443-444.
54. Beardsley J.R., Williamson J.C., Johnson J.W., et al. Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia. Chest 2006, 130(3):787-793.
55. Fowler R.A., Flavin K.E., Barr J., et al. Variability in antibiotic prescribing patterns and outcomes in patients with clinically suspected ventilator-associated pneumonia. Chest 2003, 123(3):835-844.
56. Nseir S., Di Pompeo C., Soubrier S., et al. First-generation fluoroquinolone use and subsequent emergence of multiple drug-resistant bacteria in the intensive care unit. Crit Care Med 2005, 33(2):283-289.
57. Kumar A., Zarychanski R., Light B., et al. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med 2010, 38(9):1773-1785.
58. Kett D.H., Cano E., Quartin A.A., et al. Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort study. Lancet Infect Dis 2011, 11(3):181-189.
59. Ferrer M., Liapikou A., Valencia M., et al. Validation of the American Thoracic Society-Infectious Diseases Society of America guidelines for hospital-acquired pneumonia in the intensive care unit. Clin Infect Dis 2010, 50(7):945-952.
60. Udy A.A., Roberts J.A., De Waele J.J., et al. What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance. Int J Antimicrob Agents 2012, 39(6):455-457.
61. Nicasio A.M., Eagye K.J., Nicolau D.P., et al. Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. JCrit Care 2010, 25(1):69-77.
62. Niederman M.S. The importance of de-escalating antimicrobial therapy in patients with ventilator-associated pneumonia. Semin Respir Crit Care Med 2006, 27(1):45-50.
63. Niederman M.S., Soulountsi V. De-escalation therapy: is it valuable for the management of ventilator-associated pneumonia?. Clin Chest Med 2011, 32(3):517-534.
64. Kollef M.H., Morrow L.E., Niederman M.S., et al. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest 2006, 129(5):1210-1218.
65. Soo Hoo G.W., Wen Y.E., Nguyen T.V., et al. Impact of clinical guidelines in the management of severe hospital-acquired pneumonia. Chest 2005, 128(4):2778-2787.
66. Chastre J., Wolff M., Fagon J.Y., et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003, 290(19):2588-2598.
67. Michalopoulos A., Kasiakou S.K., Mastora Z., et al. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit Care 2005, 9(1):R53-R59.
68. Niederman M.S., Chastre J., Corkery K., et al. BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia. Intensive Care Med 2012, 38(2):263-271.
69. Lu Q., Yang J., Liu Z., et al. Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011, 184(1):106-115.
70. Nseir S., Di Pompeo C., Pronnier P., et al. Nosocomial tracheobronchitis in mechanically ventilated patients: incidence, aetiology and outcome. Eur Respir J 2002, 20(6):1483-1489.
71. Palmer L.B., Smaldone G.C., Chen J.J., et al. Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit. Crit Care Med 2008, 36(7):2008-2013.
72. Shorr A.F., Zilberberg M.D., Reichley R., et al. Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department. Clin Infect Dis 2012, 54(2):193-198.
73. Grenier C., Pepin J., Nault V., et al. Impact of guideline-consistent therapy on outcome of patients with healthcare-associated and community-acquired pneumonia. JAntimicrob Chemother 2011, 66(7):1617-1624.
74. Falcone M., Corrao S., Licata G., et al. Clinical impact of broad-spectrum empirical antibiotic therapy in patients with healthcare-associated pneumonia: a multicenter interventional study. Intern Emerg Med 2012, 7(6):523-531.
75. Chalmers J.D., Taylor J.K., Singanayagam A., et al. Epidemiology, antibiotic therapy, and clinical outcomes in health care-associated pneumonia: a UK cohort study. Clin Infect Dis 2011, 53(2):107-113.
76. Attridge R.T., Frei C.R., Restrepo M.I., et al. Guideline-concordant therapy and outcomes in healthcare-associated pneumonia. Eur Respir J 2011, 38(4):878-887.
77. Schlueter M., James C., Dominguez A., et al. Practice patterns for antibiotic de-escalation in culture-negative healthcare-associated pneumonia. Infection 2010, 38(5):357-362.
78. Resar R., Pronovost P., Haraden C., et al. Using a bundle approach to improve ventilator care processes and reduce ventilator-associated pneumonia. Jt Comm J Qual Patient Saf 2005, 31(5):243-248.
79. Morris A.C., Hay A.W., Swann D.G., et al. Reducing ventilator-associated pneumonia in intensive care: impact of implementing a care bundle. Crit Care Med 2011, 39(10):2218-2224.
80. Caserta R.A., Marra A.R., Durao M.S., et al. Aprogram for sustained improvement in preventing ventilator associated pneumonia in an intensive care setting. BMC Infect Dis 2012, 12:234.
81. DeRiso A.J., Ladowski J.S., Dillon T.A., et al. Chlorhexidine gluconate 0.12% oral rinse reduces the incidence of total nosocomial respiratory infection and nonprophylactic systemic antibiotic use in patients undergoing heart surgery. Chest 1996, 109(6):1556-1561.
82. Pileggi C., Bianco A., Flotta D., et al. Prevention of ventilator-associated pneumonia, mortality and all intensive care unit acquired infections by topically applied antimicrobial or antiseptic agents: a meta-analysis of randomized controlled trials in intensive care units. Crit Care 2011, 15(3):R155.
83. Lacherade J.C., De Jonghe B., Guezennec P., et al. Intermittent subglottic secretion drainage and ventilator-associated pneumonia: a multicenter trial. Am J Respir Crit Care Med 2010, 182(7):910-917.
84. Bouza E., Perez M.J., Munoz P., et al. Continuous aspiration of subglottic secretions in the prevention of ventilator-associated pneumonia in the postoperative period of major heart surgery. Chest 2008, 134(5):938-946.
85. Dreyfuss D., Djedaini K., Weber P., et al. Prospective study of nosocomial pneumonia and of patient and circuit colonization during mechanical ventilation with circuit changes every 48 hours versus no change. Am Rev Respir Dis 1991, 143(4 Pt 1):738-743.
86. Kollef M.H., Afessa B., Anzueto A., et al. Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia: the NASCENT randomized trial. JAMA 2008, 300(7):805-813.
87. Lorente L., Blot S., Rello J. New issues and controversies in the prevention of ventilator-associated pneumonia. Am J Respir Crit Care Med 2010, 182(7):870-876.